Fig. 3: Comparative analysis of cfDNA mutations and their concordance with corresponding tissue samples.

Patients were assigned to a sub-group based on A high-input and B low-input cfDNA samples used for NGS analysis (≥30 and <30 ng, respectively). FIC Ficoll-enriched CTCs, LB liquid biopsy, LR local recurrence, NGS next-generation sequencing, ROS RosetteSep™-enriched CTCs, tDNA tumor-derived DNA.